KendraLynnSweetMD

Hematologic Oncology

Physician

Overview of Dr. Sweet

Dr. Kendra Sweet is an oncologist in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute and James A. Haley Veterans' Hospital-Tampa. She received her medical degree from Virginia Commonwealth University School of Medicine and has been in practice 10 years. Dr. Sweet accepts several types of health insurance, listed below. She is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute and one of 50 doctors at James A. Haley Veterans' Hospital-Tampa who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Book by Phone+1(816) 656-3009

Education & Training

University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 2007 - 2010
Virginia Commonwealth University School of MedicineClass of 2007

Certifications & Licensure

FL State Medical License 2010 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) Start of enrollment: 2013 Aug 29
Completed
Phase 2
SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia Start of enrollment: 2014 Sep 01
Completed
Phase 1, Phase 2
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors Start of enrollment: 2019 Nov 19
Recruiting
Phase 2
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia Start of enrollment: 2018 Oct 24
Active, not recruiting
Phase 2
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS Start of enrollment: 2019 May 20
Recruiting
Phase 1
Quality of Life Model for Older Patients With AML Start of enrollment: 2020 Jul 08
Active, not recruiting
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA Start of enrollment: 2021 Mar 30
Recruiting
Phase 1, Phase 2
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Start of enrollment: 2018 Aug 15
Recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

150 citations
Chronic myeloid leukemia, version 2.2021
Michael W. Deininger, Neil P. Shah, Jessica K. Altman, Ellin Berman, Ravi Bhatia
Journal of the National Comprehensive Cancer Network. 2020-10-01
35 citations
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML).
Seongseok Yun, Susan Geyer, Rami S. Komrokji, Najla Al Ali, Jinming Song
Leukemia. 2021-04-01
19 citations
Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC).
Seongseok Yun, Rohit Sharma, Onyee Chan, Nicole D. Vincelette, David A. Sallman
Leukemia Research. 2019-09-01

Journal Articles

A Phase I Clinical Trial of Ruxolitinib in Combination with Nilotinib in Chronic Myeloid Leukemia Patients with Molecular Evidence of Disease
Kendra Sweet, Fadi Kayali, Javier Pinilla-Ibarz, Leukemia Research
A Phase I Clinical Trial of Ruxolitinib in Combination with Nilotinib in Chronic Myeloid Leukemia Patients with Molecular Evidence of Disease
Kendra Sweet, Fadi Kayali, Javier Pinilla-Ibarz, Leukemia Research

Abstracts/Posters

SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome
Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/7/2019
Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendriti...
Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (_60 Years Old) with Ac...
Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic ...
Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients _70 Years with Acute M...
Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of ...
Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation
Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation
Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes
Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acu...
Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation
Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State
Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

A Phase I Clinical Trial of Ruxolitinib in Combination with Nilotinib in Chronic Myeloid Leukemia Patients with Molecular Evidence of DiseaseOctober 2018
State of the Art Update and Next Questions: Acute Myeloid LeukemiaOctober 2017

Press Mentions

Adding Ruxolitinib to TKI Treatments Enhances Molecular Response in Chronic Myeloid LeukemiaSeptember 24th, 2024
S1712 Supports Adding Ruxolitinib to TKIs for CMLSeptember 20th, 2024
Leukemia Patients Consider Stopping Drug to See if They’re CuredDecember 12th, 2019

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment